In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

In the latest close session, Moderna (MRNA) was down 1.48% at $47.99. The stock fell short of the S&P 500, which registered a gain of 0.5% for the day. Elsewhere, the Dow gained 0.64%, while the ...

Shares of Moderna MRNA rose 13% in the past week after the company announced preliminary sales for the full-year 2025, as ...

Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ: MRNA) has quietly muscled its way into the top year-to-date performers, up more than 20% ...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer ...

The technical backdrop, however, points to caution. Seeking Alpha's momentum page flags Moderna as overbought on its relative strength index, with RSI levels indicating the stock has sprinted ahead of ...